Beximco Pharmaceuticals Limited (“BPL” or “the Company”), the fast-growing manufacturer of generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids, today announces that it has received GMP (“Good Manufacturing Practices”) accreditation from Taiwan Food and Drug Administration (TFDA) as the first Bangladeshi company. The company has received the approval for its oral solid, Inhaler and sterile eye drop facilities.
Taiwan FDA is considered as one of the most stringent regulatory agencies in the globe and by obtaining the GMP approval Beximco Pharma has added another sterling feather in its cap. This prestigious and valuable achievement opens new marketing opportunity for Beximco Pharma’s products in ASEAN market including Taiwan, which is one of the advanced pharmaceutical markets in Asia. Like several other developed countries, Taiwan is increasingly promoting access to generic drugs which offers opportunities for generic drug companies like Beximco Pharma as until today only a few generic companies have Taiwan FDA approval.
This significant milestone validates Beximco Pharma’s commitment to the quality and continuous efforts to expand its business around the globe. The company is currently exporting to many countries around the world and its world class manufacturing facilities have already received GMP approvals from global regulatory authorities including AGES (EU), TGA (Australia) and ANVISA (Brazil).
“We are very pleased to reach such an important milestone with the Taiwan FDA approval” said Nazmul Hassan, Managing Director of Beximco Pharma, “This approval is a testimony to the high standards of quality and compliance practices put in place by the Company. This is an important step towards our aspiration to become a global generic drug player and particularly for building our presence in the regulated markets’’